This is a preview. Log in through your library . Abstract Background. A notable reduction of the pneumococcal disease burden among adults was observed after the introduction of a 7-valent pneumococcal ...
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from ...
10 يومon MSN
Promising preclinical therapy exploits ALK protein to selectively destroy tumors while sparing healthy cells
Researchers at Children's Hospital of Philadelphia (CHOP) unveiled a novel antibody-drug conjugate (ADC) that shows striking ...
NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Medicovestor, Inc, a privately-held biopharmaceutical company focused on the development of novel antibody drug-conjugate (ADC) therapies, proudly announces ...
News-Medical.Net on MSN
Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug ...
تظهر حاليًا النتائج التي قد لا يمكن الوصول إليها.
إخفاء النتائج التي لا يمكن الوصول إليها
ملاحظات